Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

H2-antagonists and carmustine.

R T Dorr1, M J Soble

  • 1Arizona Cancer Center, University of Arizona, Department of Internal Medicine and Pharmacology/Toxicology, Tucson.

Journal of Cancer Research and Clinical Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemistry and pharmacology of imexon and related cyanoaziridines.

Current medicinal chemistry·2012
Same author

Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.

Bone marrow transplantation·2003
Same author

Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.

Journal of medicinal chemistry·2001
Same author

Drug interactions with the taxanes: clinical implications.

Cancer treatment reviews·2001
Same author

Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.

Anti-cancer drugs·2001
Same journal

TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy.

Journal of cancer research and clinical oncology·2026
Same journal

GALNT5 drives colorectal cancer progression and chemoresistance via PI3K/Akt/ABCC1 axis.

Journal of cancer research and clinical oncology·2026
Same journal

Editorial Expression of Concern: Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas.

Journal of cancer research and clinical oncology·2026
Same journal

Nano-biosensors for circulating tumor markers: advancing liquid biopsy toward precision cancer diagnostics.

Journal of cancer research and clinical oncology·2026
Same journal

Predictive value of folate receptor-positive circulating tumor cells in postoperative progressive disease of non-small cell lung cancer patients.

Journal of cancer research and clinical oncology·2026
Same journal

Stained region lymph node biopsy for axillary restaging after neoadjuvant systemic therapy in node-positive breast cancer: a cohort study.

Journal of cancer research and clinical oncology·2026
See all related articles

Cimetidine enhances carmustine (BCNU) anticancer effects and bone marrow toxicity by impairing drug clearance. Ranitidine showed minor enhancement of BCNU

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Metabolism

Background:

  • Carmustine (BCNU) is a DNA-alkylating nitrosourea anticancer agent.
  • Cytochrome P-450 enzymes extensively metabolize BCNU into active and inactive compounds.
  • Histamine H2 antagonists can alter the toxicity of other highly metabolized anticancer drugs.

Purpose of the Study:

  • To investigate the impact of cimetidine (CMT) and ranitidine (RNT) coadministration on BCNU toxicity and efficacy.
  • To determine if histamine H2 antagonists affect BCNU's pharmacokinetic profile.

Main Methods:

  • DBA/2J mice received BCNU with varying timings of CMT or RNT administration.
  • Spleen colony assays assessed normal bone marrow stem cell viability.
  • P-388 leukemia models evaluated antitumor effects.

Related Experiment Videos

  • Pharmacokinetic analyses measured BCNU elimination rates.

    • Main Results:

    • Coadministration with CMT significantly enhanced BCNU's bone marrow toxicity.
    • Both CMT and RNT increased BCNU's antitumor effects in leukemia models.
    • CMT markedly prolonged BCNU elimination and increased drug exposure.
    • RNT showed minimal impact on BCNU myelotoxicity and pharmacokinetics.

    Conclusions:

    • Cimetidine enhances BCNU's toxicity and antitumor activity, likely due to reduced BCNU clearance.
    • Ranitidine has a limited effect on BCNU's myelotoxicity and elimination.
    • Drug interactions between BCNU and histamine H2 antagonists warrant further investigation.